vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and Penumbra Inc (PEN). Click either name above to swap in a different company.
Penumbra Inc is the larger business by last-quarter revenue ($385.4M vs $360.9M, roughly 1.1× LivaNova PLC). Penumbra Inc runs the higher net margin — 12.3% vs 8.6%, a 3.7% gap on every dollar of revenue. On growth, Penumbra Inc posted the faster year-over-year revenue change (22.1% vs 12.1%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $50.2M). Over the past eight quarters, Penumbra Inc's revenue compounded faster (17.6% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.
LIVN vs PEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $385.4M |
| Net Profit | $30.9M | $47.3M |
| Gross Margin | 65.2% | 68.0% |
| Operating Margin | 11.8% | 15.4% |
| Net Margin | 8.6% | 12.3% |
| Revenue YoY | 12.1% | 22.1% |
| Net Profit YoY | -44.7% | 40.6% |
| EPS (diluted) | $0.57 | $1.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $385.4M | ||
| Q3 25 | $357.8M | $354.7M | ||
| Q2 25 | $352.5M | $339.5M | ||
| Q1 25 | $316.9M | $324.1M | ||
| Q4 24 | $321.8M | $315.5M | ||
| Q3 24 | $318.1M | $301.0M | ||
| Q2 24 | $318.6M | $299.4M | ||
| Q1 24 | $294.9M | $278.7M |
| Q4 25 | $30.9M | $47.3M | ||
| Q3 25 | $26.8M | $45.9M | ||
| Q2 25 | $27.2M | $45.3M | ||
| Q1 25 | $-327.3M | $39.2M | ||
| Q4 24 | $55.9M | $33.7M | ||
| Q3 24 | $33.0M | $29.5M | ||
| Q2 24 | $16.3M | $-60.2M | ||
| Q1 24 | $-41.9M | $11.0M |
| Q4 25 | 65.2% | 68.0% | ||
| Q3 25 | 68.4% | 67.8% | ||
| Q2 25 | 67.8% | 66.0% | ||
| Q1 25 | 69.7% | 66.6% | ||
| Q4 24 | 68.2% | 66.8% | ||
| Q3 24 | 70.8% | 66.5% | ||
| Q2 24 | 68.7% | 54.4% | ||
| Q1 24 | 70.3% | 65.0% |
| Q4 25 | 11.8% | 15.4% | ||
| Q3 25 | 15.1% | 13.8% | ||
| Q2 25 | 15.4% | 12.0% | ||
| Q1 25 | 15.3% | 12.4% | ||
| Q4 24 | 11.5% | 13.6% | ||
| Q3 24 | 11.2% | 11.7% | ||
| Q2 24 | 12.6% | -27.0% | ||
| Q1 24 | 5.5% | 4.3% |
| Q4 25 | 8.6% | 12.3% | ||
| Q3 25 | 7.5% | 12.9% | ||
| Q2 25 | 7.7% | 13.3% | ||
| Q1 25 | -103.3% | 12.1% | ||
| Q4 24 | 17.4% | 10.7% | ||
| Q3 24 | 10.4% | 9.8% | ||
| Q2 24 | 5.1% | -20.1% | ||
| Q1 24 | -14.2% | 3.9% |
| Q4 25 | $0.57 | $1.20 | ||
| Q3 25 | $0.49 | $1.17 | ||
| Q2 25 | $0.50 | $1.15 | ||
| Q1 25 | $-6.01 | $1.00 | ||
| Q4 24 | $1.04 | $0.88 | ||
| Q3 24 | $0.60 | $0.75 | ||
| Q2 24 | $0.30 | $-1.55 | ||
| Q1 24 | $-0.78 | $0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $186.9M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $1.4B |
| Total Assets | $2.6B | $1.8B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $186.9M | ||
| Q3 25 | $646.1M | $321.0M | ||
| Q2 25 | $593.6M | $421.8M | ||
| Q1 25 | $738.4M | $376.1M | ||
| Q4 24 | $428.9M | $324.4M | ||
| Q3 24 | $346.4M | $280.5M | ||
| Q2 24 | $329.2M | $288.3M | ||
| Q1 24 | $309.2M | $223.1M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $2.6B | $1.8B | ||
| Q3 25 | $2.6B | $1.7B | ||
| Q2 25 | $2.5B | $1.7B | ||
| Q1 25 | $2.6B | $1.6B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | $2.5B | $1.6B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $86.5M |
| Free Cash FlowOCF − Capex | $50.2M | $68.0M |
| FCF MarginFCF / Revenue | 13.9% | 17.7% |
| Capex IntensityCapex / Revenue | 8.9% | 4.8% |
| Cash ConversionOCF / Net Profit | 2.67× | 1.83× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $174.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $86.5M | ||
| Q3 25 | $85.1M | $58.3M | ||
| Q2 25 | $62.9M | $44.9M | ||
| Q1 25 | $24.0M | $49.0M | ||
| Q4 24 | $78.7M | $51.1M | ||
| Q3 24 | $51.0M | $56.5M | ||
| Q2 24 | $43.4M | $22.6M | ||
| Q1 24 | $10.0M | $38.3M |
| Q4 25 | $50.2M | $68.0M | ||
| Q3 25 | $62.2M | $42.0M | ||
| Q2 25 | $47.8M | $29.4M | ||
| Q1 25 | $13.2M | $35.5M | ||
| Q4 24 | $68.3M | $45.7M | ||
| Q3 24 | $32.8M | $51.0M | ||
| Q2 24 | $31.2M | $18.1M | ||
| Q1 24 | $3.6M | $32.5M |
| Q4 25 | 13.9% | 17.7% | ||
| Q3 25 | 17.4% | 11.8% | ||
| Q2 25 | 13.6% | 8.7% | ||
| Q1 25 | 4.2% | 11.0% | ||
| Q4 24 | 21.2% | 14.5% | ||
| Q3 24 | 10.3% | 16.9% | ||
| Q2 24 | 9.8% | 6.0% | ||
| Q1 24 | 1.2% | 11.7% |
| Q4 25 | 8.9% | 4.8% | ||
| Q3 25 | 6.4% | 4.6% | ||
| Q2 25 | 4.3% | 4.6% | ||
| Q1 25 | 3.4% | 4.2% | ||
| Q4 24 | 3.2% | 1.7% | ||
| Q3 24 | 5.7% | 1.8% | ||
| Q2 24 | 3.8% | 1.5% | ||
| Q1 24 | 2.2% | 2.1% |
| Q4 25 | 2.67× | 1.83× | ||
| Q3 25 | 3.18× | 1.27× | ||
| Q2 25 | 2.32× | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | 1.41× | 1.52× | ||
| Q3 24 | 1.55× | 1.91× | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | 3.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
